In order to understand the structure and functioning of the brain, neuroscientists need to study the complex, three-dimensional pathways and connections of nerve fibers. The intersection of multiple nerve fibers poses a particular challenge for neuroimaging.
Matthew Dean, Sales Engineer and Head of the Medical Business Unit at maxon, explores how Newrotex and maxon are developing an innovative approach to overcome the common challenges of traditional nerve repair.
In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) restored insulin production and ended severe hypoglycemia in adults with type 1 diabetes within a year of treatment.
Washington State University and Mayo Clinic researchers have developed an electrochemical catheter hub that could someday help prevent deadly central line-associated bloodstream infections (CLABSIs) that annually kill thousands of people around the world.
Opioids like fentanyl, morphine and oxycodone are the drugs most linked to overdoses in the U.S. Typical screening methods for drug usage involve collection of blood, saliva or urine samples. Now, in Analytical Chemistry, researchers demonstrate a pen-like tool that can quickly and non-invasively collect molecules from the skin’s surface to be screened for opioids with mass spectrometry.
Using stem cells from patients with ALS (amyotrophic lateral sclerosis), Cedars-Sinai has created a lifelike model of the mysterious and fatal disease that could help identify a cause of the illness as well as effective treatments.
IRVINE, Calif. and ABU DHABI, UAE, June 24, 2025 /PRNewswire/ — Ocutrx Technologies Inc. (“Ocutrx”), through its R&D division Genius Labs, today unveiled a major surgical innovation: the ability to render blood translucent in real time during surgery. This patent-pending advancement enables surgeons to see through pooled blood without the need for suction or irrigation—a world first. The technology, called HemoLucence™, will be a feature of the OR-Bot™ 3D Surgical Microscope System, which is scheduled to enter clinical trials in 2025 or 2026.
Glucotrack (Nasdaq:GCTK) believes it can tap into a diabetes market that includes millions of people who aren’t being served completely.
Watery fluid between cells plays a major role, offering new insights into how organs and tissues adapt to aging, diabetes, cancer, and more.
Scientists from the National University of Singapore (NUS) have developed NAPTUNE (Nucleic Acids and Protein biomarkers Testing via Ultra-sensitive Nucleases Escalation), a point-of-care assay that identifies trace amounts of disease-related genetic material, including nucleic acid and protein markers, in less than 45 minutes. Importantly, it accomplished this without the need for laboratory equipment or complex procedures.